-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Maze Therapeutics, Raises Price Target to $46

Benzinga·01/16/2026 17:24:34
Listen to the news
BTIG analyst Julian Harrison maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target from $37 to $46.